This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

OverviewDosingTolerability ProfileSupport and ResourcesFluoropyrimidine intoleranceUse in patients with fluoropyrimidine intolerancePatient profiles
Explore more
MaterialsVideosEvents

Prescribing Information for TOMUDEX® (raltitrexed) and adverse event reporting information can be found at the bottom of the page.


Patient Profiles

Consider TOMUDEX as an alternative treatment option when fluoropyrimidine treatment is not tolerated1

Patient 1 - Case of acute coronary syndrome associated with continuous intravenous 5-fluorouracil (5-FU) infusion2:
 


Patient Characteristics

  • 55 years old 
  • Female
  • Non-smoker  

Clinical History

  • Presented with colonic obstructive symptoms and anaemia – diagnosed with an adenocarcinoma of the sigmoid 
  • Urgent left hemicolectomy showed a moderately differentiated adenocarcinoma that perforated the visceral peritoneum, had disseminated to fifteen regional lymph nodes and there were several metastatic hepatic nodules
  • No history of previous coronary artery disease, congestive heart failure, diabetes mellitus, hypercholesterolaemia or hypertension
  • No family history of heart disease
  • ECHO and ECG showed no alterations
  • History of limb thrombosis, managed with warfarin* treatment

Chemotherapy Treatment Regimen 

  • Palliative chemotherapy with mFOLFOX6 regimen – folinic acid 400mg/m2 plus oxaliplatin 85mg/m2, IV in 2 hours plus 5-FU 400mg/m2 in bolus plus 5-FU 2400 mg/m2, IV continuous infusion in 46 hours

Current Presentation 

  • Retrosternal burning pain
  • Abnormal ECG
  • Mild elevations of cardiac enzymes
  • Increased INR
  • ECHO showed global left hypokinesis

OutcomeAcute coronary syndrome probably secondary to arterial vasospasm associated with continuous intravenous 5-FU infusion
 

Could this CRC patient be a candidate for TOMUDEX? 
 

Note: Leucovorin (folinic acid), folic acid or vitamin preparations containing these agents must not be given immediately prior to or during administration of raltitrexed, since they may interfere with its action.

Patient 2 - Case of 5-FU induced cardiotoxicity in a patient with coronary artery disease3:
 


Patient Characteristics

  • 62 years old 
  • Male

Clinical History  

  • Presented with unresectable liver metastases of a sigmoid adenocarcinoma  
  • History of coronary artery disease with two myocardial infractions 14 and 22 years ago, received coronary bypass grafts to the left anterior descending artery (LAD) and the left circumflex artery (LCX) 12 years prior. 
  • Taking a long acting nitrate and aspirin**. 
  • ECG shows signs of myocardial scar but otherwise normal.

Chemotherapy Treatment Regimen 

  • Weekly treatment with folinic acid 500mg/m2 given as a 2-hour infusion followed by 5-FU 2600mg/m2 as a 24h infusion

Current Presentation 

  • Retrosternal chest pain
  • ECG showing non-specific ST segment elevation in anterior leads and T-wave inversion in lead III
  • Serial serum cardiac enzyme measurements unchanged
  • Coronary angiography demonstrates severe stenosis of LAD bypass graft and a moderate stenosis of LCX bypass graft

Outcome: 5-FU induced cardiotoxicity and ischaemic heart disease.


Could this CRC patient be a candidate for TOMUDEX?
 

Note: Leucovorin (folinic acid), folic acid or vitamin preparations containing these agents must not be given immediately prior to or during administration of raltitrexed, since they may interfere with its action.

Dosing

Learn about treatment with TOMUDEX and required dosing adjustments 

Learn moreLoading
Fluoropyrimidine Intolerance

Explore more about TOMUDEX use in patients with fluoropyrimidine intolerance

Explore moreLoading
Tolerability Profile

Find out more about the tolerability profile of TOMUDEX

Find out moreLoading
Medicines

Find out more about other Pfizer products

View MedicinesLoading
Join us!

Sign up or log in now to access further materials and resource

Join NowLoading

Abbreviations:
 

5-FU, 5-fluorouracil; CRC, colorectal cancer; ECG, electrocardiogram; ECHO, echocardiogram; LAD, left anterior descending artery; LCX, left circumflex artery; INR, international normalised ratio; IV, intravenous; mFOLFOX6, modified FOLFOX-6 regimen 


Footnotes:


*Raltitrexed is 93% protein bound and while it has the potential to interact with similarly highly protein bound drugs, no displacement interaction with warfarin has been observed in vitro. However, a review of the clinical trial safety database did not reveal evidence of clinically significant interaction in patients treated with raltitrexed who also received concomitant warfarin.

**Data suggest that active tubular secretion may contribute to the renal excretion of raltitrexed, indicating a potential interaction with other actively secreted drugs such as non-steroidal anti-inflammatory drugs (NSAIDS). However, a review of the clinical trial safety database did not reveal evidence of clinically significant interaction in patients treated with raltitrexed who also received concomitant NSAIDS.


References:

  1. TOMUDEX® Summary of Product Characteristics.
  2. Paiva CE et al. J Gastrointest Canc 2009; 40:133-137.
  3. Kohne C-H, Thuss-Patience P et al. British J Cancer 1998; 77:6:973-977.


 

Prescribing Information

TOMUDEX:

TOMUDEX® (raltitrexed) 2 mg powder for solution for infusion – Prescribing Information Legal Category: POM. Basic NHS Price: 1 vial £148.75
 

OXALIPLATIN:

Oxaliplatin Vial 50mg/10ml Legal Category: POM. Basic NHS Price: 1 vial £156.75
Oxaliplatin Vial 100mg/20ml Legal Category: POM. Basic NHS Price: 1 vial £313.50
Oxaliplatin Vial 200mg/40ml Legal Category: POM. Basic NHS Price: 1 vial £627.00
Oxaliplatin 5mg/ml Concentrate for Solution for Infusion - Prescribing Information 


FLUOROURACIL:

Fluorouracil Vial 500mg/20ml Legal Category: POM. Basic NHS Price: £64.00
Fluorouracil Vial 25mg/ml Legal Category: POM. Basic NHS Price: £32.00
Fluorouracil 25mg/ml Injection - Prescribing Information

Fluorouracil Vial 50mg/ml Legal Category: POM. Basic NHS Price: £64.00
Fluorouracil Vial 500mg/10ml Legal Category: POM. Basic NHS Price: £32.00
Fluorouracil Vial 2.5g/50ml Legal Category: POM. Basic NHS Price: £32.00
Fluorouracil 50mg/ml Injection - Prescribing Information

PP-TOM-GBR-0001. July 2022

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7866. January 2024
You are now leaving PfizerPro​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 
Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro ​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro​​​​​

​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​